Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Classical hematology 1

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 3beta-Thalassemia 1Primary Myelofibrosis 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Anemia 1

Interventions

Specimen Handling 602pembrolizumab 557Magnetic Resonance Spectroscopy 527Carboplatin 422Cyclophosphamide 370Cisplatin 369Biopsy 349Paclitaxel 304Gemcitabine 299Nivolumab 298Radiotherapy 256Bevacizumab 232Dexamethasone 207fludarabine 203Docetaxel 185durvalumab 177atezolizumab 172Oxaliplatin 170Fluorouracil 166venetoclax 164Rituximab 163Pemetrexed 161Doxorubicin 157Radiation 155Capecitabine 155Radiosurgery 145Etoposide 137Leucovorin 133Ipilimumab 132Lenalidomide 129

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × luspatercept × 90 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡